How to predict carboplatin clearance from standard morphological and biological charactersties in obese patients

Annals of Oncology

Volumn 8, Issue 6, 1997, Pages 607-609

  Benezet S ^a   Guimbaud, R ^a   Chatelut, E ^a   Chevreau, C ^b   Bugat, R ^b   Canal, P ^b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Carboplatin; Dose adaptation; Ideal weight; Obesity; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CREATININE;

ADULT; AGED; AGING; ARTICLE; BLOOD; BODY WEIGHT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; OBESITY; PHYSIOLOGY; PREDICTION AND FORECASTING; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CARBOPLATIN; CREATININE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; OBESITY; PREDICTIVE VALUE OF TESTS; SEX FACTORS;

EID: 0031155476     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008259009500     Document Type: Article

References (8)

1. Chatclut E. Canal P. Brunncr et al. Prediction of carboplalin clearance from standard morphological and biological patient characteristics. .1 Nail Cancer Inst 1995: 8n: 5T3-80.
2. van Wamerdam LJC. Rodenhuis S. ten Bokkel Huinink WWet al. Evaluation of formulas using the scrum creatinine level to calculate ihe optimal dosage ofcarboplatin. Cancer Chemoiher Pharmacol 1996: 37: 266 70.
3. Lorentz FH. Der konstiîutionsindex der frau. Klin Vv'ochenshr 1929: 16: 734-6.
4. Beal SL. S.ieiner LB. Meihociology of population pharmacoklnetics. In Garren ER. Kirtz j (eds): Drug Fate and Metabolism (Vol. 5). Na\v York: Marcel Decker 1985: 135-83.
5. Sawyer W I. Canaday BR. Poe TE et al. Variables affecting creatinine clearance prediction. Am j Hosp Pharm 1983: 40: 2175 80.
6. Cockcrofl DW. Gault MH. Prediction of creatinine clearance from serum creatinine. Kephron 1976: 16: 31-41.
7. Cal\en AH. Newerl DR. Gumbrell LA et al. Carbopiatin dosage: Prospective evaluation of a simple formula based on renai function. J Clin Oncol 19S9: 7: 1748-56.
8. Calvcrt AH. Boddy A. Bailey NPet al. Carbopiatin in combination with paclhaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodvuamic interactions. Semin Oncol 1995: 5 (Suppl 12): 91-8.